VMD
Viemed Healthcare, Inc.7.26
-0.11-1.49%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
281.58MP/E (TTM)
21.35Basic EPS (TTM)
0.34Dividend Yield
0%Recent Filings
8-K
10-Q
10-Q
Q2 FY2025 results
Viemed Healthcare posted solid Q2 results, with revenue climbing 14.7% year-over-year to $63.1 million, fueled by 11.1% growth in ventilator rentals to $33.8 million and 29.0% in equipment sales to $9.5 million, while gross margin dipped to 58.3% from 59.8% on a shifting revenue mix. Operating income jumped 40.9% to $5.1 million, and diluted EPS held at $0.08, aligning with 41.1 million weighted shares. Cash from operations hit $15.1 million year-to-date, up from $11.4 million, boosting cash to $20.0 million despite $23.6 million in capex; total debt stayed low at $4.3 million under the 2022 facilities maturing 2027, with full covenant compliance. The April 2024 HomeMed buy added $3.2 million goodwill, and July's $26 million Lehan's deal—funded by $18 million debt and cash—eyes geographic gains. Revenue relies heavily on Medicare, now 40% of total.
8-K
Record Q2 revenues, acquisition closed
Viemed Healthcare reported record Q2 2025 net revenues of $63.1 million, up 14.7% year-over-year, with net income surging 115% to $3.2 million amid robust patient growth in ventilators (up 11.4% to 12,152) and PAP therapy (up 51.4% to 26,260). Adjusted EBITDA rose 11.5% to $14.3 million, bolstered by favorable product mix and expense leverage. The company closed its $26 million acquisition of Lehan's Medical Equipment on July 1, prompting raised full-year guidance to $271–277 million in revenue and $59–62 million in Adjusted EBITDA. Integration challenges could temper synergies.
8-K
Viemed closes Lehan acquisition
Viemed Healthcare completed its acquisition of Illinois-based Lehan's Medical Equipment on July 2, 2025, for a base price of $26 million plus $2.2 million in estimated contingent payments, funded by cash and borrowings. Lehan, with 2024 net revenues of $25.7 million and Adjusted EBITDA of $7.4 million, bolsters Viemed's home medical equipment offerings in a fast-growing market. The deal integrates Lehan's regional expertise with Viemed's national scale. Viemed plans to update its 2025 guidance in Q2 earnings. Integration challenges loom large.
AHCO
AdaptHealth Corp.
10.35+0.08
ELMD
Electromed, Inc.
29.88+0.28
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
LIVN
LivaNova PLC
63.08+0.02
MDT
Medtronic plc.
97.72-0.85
QIPT
Quipt Home Medical Corp.
3.52+0.02
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
VVOS
Vivos Therapeutics, Inc.
2.02+0.00